Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma by Ognjanovic, Simona et al.
Hindawi Publishing Corporation
Sarcoma
Volume 2012, Article ID 492086, 6 pages
doi:10.1155/2012/492086
Research Article
LowPrevalenceofTP53 Mutations and MDM2 Ampliﬁcations in
Pediatric Rhabdomyosarcoma
SimonaOgnjanovic,1,2,3 GhyslaineMartel,4 CarlosManivel,5 Magali Olivier,4
EricaLanger,1 andPierre Hainaut4
1Division of Pediatric Epidemiology and Clinical Research, University of Minnesota, 420 Delaware Street SE, MMC 422, Minneapolis,
MN 55455, USA
2Masonic Cancer Center, University of Minnesota, 425 E. River Road, 554 MCRB, Minneapolis, MN 55455, USA
3Department of Pediatrics, University of Minnesota MMC 715, 420 Delaware Street SE, Minneapolis MN 55455, USA
4Section of Molecular Carcinogenesis, International Agency for Research on Cancer, 150 Cours Albert Thomas,
69372 Lyon Cedex 08, France
5Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA
Correspondence should be addressed to Simona Ognjanovic, ognja001@umn.edu
Received 4 November 2011; Accepted 28 December 2011
Academic Editor: Clement Trovik
Copyright © 2012 Simona Ognjanovic et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
The tumor suppressor gene TP53 is the most commonly mutated gene in human cancer. The reported prevalence of mutations
in rhabdomyosarcoma (RMS) varies widely, with recent larger studies suggesting that TP53 mutations in pediatric RMS may be
extremely rare. Overexpression of MDM2 also attenuates p53 function. We have performed TP53 mutation/MDM2 ampliﬁcation
analyses in the largest series analyzed thus far, including DNA isolated from 37 alveolar and 38 embryonal RMS tumor samples
obtained from the Cooperative Human Tissue Network (CHTN). Available samples were frozen tumor tissues (N = 48) and
histopathology slides. TP53 mutations in exons 4–9 were analyzed by direct sequencing in all samples, and MDM2 ampliﬁcation
analysis was performed by diﬀerential PCR on a subset of 22 samples. We found only one sample (1/75, 1.3%) carrying a TP53
mutationatcodon259(p.D259Y)andnoMDM2ampliﬁcation.TwoSNPsintheTP53pathway,associatedwithaccelerated tumor
onset in germline TP53 mutation carriers, (TP53 SNP72 (rs no. 1042522) and MDM2 SNP309 (rs no. 2279744)), were not found
to confer earlier tumor onset. In conclusion, we conﬁrm the extremely low prevalence of TP53 mutations/MDM2 ampliﬁcations
in pediatric RMS (1.33% and 0%, respectively). The possible inactivation of p53 function by other mechanisms thus remains to
be elucidated.
1.Introduction
Rhabdomyosarcoma (RMS) is the most common type of
soft tissue sarcoma diagnosed in children under the age of
15 years contributing to approximately 4% of all childhood
malignancies [1]. Two major subtypes, embryonal (ERMS)
andalveolarrhabdomyosarcoma(ARMS),togethercomprise
80% of all rhabdomyosarcoma [2]. The predominant sub-
type is ERMS which is characterized by earlier age of onset
and better survival compared to ARMS (70% versus 50%,
resp.) [2, 3]. While ERMS is characterized by frequent loss
of imprinting on chromosome 11p15, a region containing a
number of imprinted genes, including IGF2, 80% of ARMS
present with translocations, most frequently involving PAX
3 or 7 and FOXO gene rearrangements [4, 5]. Young age of
onset, a number of identiﬁed predisposing syndromes, and
paucity of environmental and lifestyle risk factors all con-
tribute to the widely accepted view that genetic aberrations
may play an important role in RMS development [3, 5].
However, the etiology of RMS remains largely unknown
primarily due to its rarity and diagnostic diversity [2].
TP53 is the most commonly mutated gene in human
cancer; however, the prevalence of TP53 mutations varies
greatly by cancer type [6] .T h i st u m o rs u p p r e s s o rg e n ei s
activated in response to DNA damage and mediates cell cycle2 Sarcoma
arrest or induction of apoptosis. MDM2 is a key negative
regulator of p53 expression; binding of MDM2 to p53 targets
p53 for proteasomal degradation. Therefore, overexpression
of MDM2 attenuates p53 function.
Missense mutations are the most common mechanisms
of TP53 inactivation [7]. Frequently mutations are clustered
in exons 5 through 8 [7], the region coding for the DNA
binding domain, where “hotspot mutations” have been de-
scribed. In addition, a number of variants in the TP53
gene have been described, and some of these, including
SNP72 (rs no. 1042522, C/G), may modify the risk of cancer
development [8]. SNP72 is a coding SNP producing proteins
with slightly diﬀerent properties. In particular, compared
to the 72Arg (C allele) variant, the 72Pro (G allele) has a
lower aﬃnity for MDM2 [9]. This variant has been shown
to aﬀect the age of tumor onset in patients who carry a
germlinemutationinTP53[10].Similarly,acceleratedtumor
formation in germline TP53 carriers wasobserved in carriers
of the minor allele (G) for the MDM2 SNP309 [11, 12]. The
TP53 SNP72 C allele has been shown to interact with the
MDM2 SNP309 G allele to amplify the risk of tumor onset
at an earlier age in carriers [10].
The risk of RMS development increased in TP53 muta-
tion carriers, but the role of the TP53 polymorphisms de-
scribed above on the age of cancer onset has not been ex-
plored in sporadic RMS.
TP53 mutations have been studied in RMS, but the ma-
jority of these studies had small sample sizes and the prev-
alence of reported mutations varied greatly (Table 1)[ 13–
24]. Larger studies have also reported inconsistent data. For
example, Mulligan et al. [18]a n dT a y l o re ta l .[ 22]d e t e c t e d
very low frequencies of TP53 mutations, 2/31 and 1/20,
respectively, while Takahashi et al. [21]r e p o r t e dam u c h
higher mutation frequency (9/45). In addition, Taylor et al.
[22] examined ampliﬁcations of the MDM2 g e n e ,af r e q u e n t
mechanism for MDM2 overexpression in other tumor types,
and detected a very low frequency of ampliﬁcations (2/20).
We have analyzed TP53 mutations in the largest series of
RMStumorsthusfar,enablingtheanalysesbyRMSsubtypes,
as well as MDM2 ampliﬁcation status. In addition, we have
examined whether TP53 and MDM2 polymorphisms may
aﬀect the age of RMS onset and have also explored the as-
sociations between these polymorphisms and speciﬁc tumor
subtype and primary tumor site.
2.MaterialandMethods
2.1. Tumor Samples. Deidentiﬁed frozen RMS tumor tissues
(N = 40)wereobtainedfromtheCooperativeHumanTissue
Network (CHTN). Histopathology slides (N = 40) were
obtainedseparatelyfromCHTNandkindlyprovidedforthis
studybyDrBrendaWeigel(UniversityofMinnesota).Fiveof
the histology slides corresponded to ﬁve of the frozen tumor
tissues, and therefore the ﬁnal sample collection included 75
diﬀerent RMS patient tumors. CHTN houses the tissues of
Children’s Oncology Group’s (COG) pediatric solid tumor
bank, obtained after routine surgical resections performed
at COG-aﬃliated institutions across the United States and
Canada. Tumors were preserved either by snap-freezing in
liquid nitrogen and storing at −80◦Co rb yﬁ x a t i o ni n
formalin,followedbyparaﬃnembeddingforhistopathology
slides. Central review of histologic slides and clinicopatho-
logic data was performed by an anatomic pathologist at
CHTN for each sample, and histologic subtypes (embryonal
orERMS;alveolarorARMS)weredetermined.Forahandful
of samples, information on percentage of area of tissue
involvedbytumorandpercentageofnecrotictumorcellswas
available. Review of all histopathology slides was performed
by Carlos Manivel, M.D., at the University of Minnesota to
estimatethepercentageoftumorandnecrosisinthesamples.
2.2. Sequencing of the TP53 Gene. DNA was isolated from
frozen tissues by using DNeasy blood and tissue mini kit,
while DNA from histopathology slides was isolated using
QIAamp DNA Micro kit, according to the manufacturer’s
protocol (Qiagen, Valencia, CA). DNA ampliﬁcation and
TP53 sequencing were performed at the International Agen-
cy for Research on Cancer (IARC) common sequencing ser-
vice using standard procedures. Primer sequences, product
lengths, and PCR conditions are available at http://www-p53
.iarc.fr/Download/TP53 DirectSequencing IARC.pdf.P C R
products were puriﬁed using the enzyme ExoSap IT (USB),
and 7µL of each puriﬁed product was sequenced by using
BigDye Terminator v1.1 Cycle Sequencing Kit (Applied
Biosystems) according to manufacturer’s protocol. Sequenc-
ing primers were the same as the ones used for ampliﬁcation.
Sequencing reaction products were puriﬁed by using 96-well
Multiscreen ﬁltration plates (G50-Pharmacia-Millipore) and
analyzedby a 16-capillary automatedsequencer(ABIPRISM
3100 Genetic Analyzer, Applied Biosystems).
2.3. Analysis of MDM2 Ampliﬁcations. MDM2 ampliﬁcation
was analyzed by using diﬀerential PCR. The analysis was
carried out as previously described, with some modi-
ﬁcations [25]. Brieﬂy, each DNA sample isolated from
22 frozen tissue tissues was added to a PCR mix with
primers for MDM2 and primers for dopamine receptor 2
(DRD2) reference sequence. The sequences of the primers
were 5 -GAGGGCTTTGATGTTCCTGA-3  (forward) and
5 -GCTACTAGAAGTTGATGG C-3  (reverse) for MDM2,
and 5 -CCACTGAATCTGTCCTGGTATG-3  (forward) and
5 -GTGTGG CATAGTAGTTGTAGT GG-3  (reverse) for
DRD2. PCR products were analyzed by electrophoresis on
3.0% agarose gel and stained with ethidium bromide. The
intensities of the DNA products were quantiﬁed by densit-
ometry using ImageQuant Version 5.0 software (Molecular
Dynamics, Inc., Sunnyvale, CA). The MDM2/DRD2 ratio
from normal blood DNA was 0.9, with a standard variation
of 0.23. A value of more than 2.5 (2x mean + 3x SD) for
the MDM2/DRD2 ratio was regarded as positive for MDM2
ampliﬁcation [25].
2.4. Analysis of MDM2 SNP309. DNA samples were geno-
typed for the single nucleotide polymorphism (SNP) MDM2
309 using the5  nucleaseTaqmanallelicdiscrimination assay
including Taqman Universal PCR Master Mix (Applied Bios-
ystems Inc., ABI, Foster City, CA), as previously described
[11]. For each assay, there were four no template controls,Sarcoma 3
Table 1: Frequency of TP53 point mutations reported in rhabdomyosarcoma.
Study size Authors Exons sequenced Number of mutations
Location of mutations
Exon 5–8 Other
Stratton et al., [20]5 – 8 0 / 4 —
Felix et al., [15] 4–8 1/6 Exon 6: R213P
Toguchida et al., [23]2 – 1 1 0 / 4 —
≤10
Latres et al., [17]2 – 9 0 / 2
Exon 11: D393N Castresana et al., [13] 5–8 1/1 Exon 6: V218Y Y220C
W¨ url et al., [24] 4–9 2/6 Exon 7: G245S
Kusafuka et al., [16] 5–8 1/10 Exon 8: R273H
Nawa et al., [19]5 – 8 0 / 2 —
Das et al., [14]2 – 1 1 1 / 4
>10
Mulligan et al., [18] 5–8 2/31 Exon 5: G137V
Exon 8: R282W
Taylor et al., [22]5 −91 / 2 0 Exon 5: del nt
1004–1017
Takahashi et al., [21]5 −99 / 4 5
Exon 6: E204G, R209T, P223R
Exon 7: M243T, G245C, N247D, R249G
Exon 8: C291G, P295H
Total TP53 mutations 18/135 (13.3%)
four controls speciﬁc for the wild-type allele, and four
controls speciﬁc for the variant allele. Completed PCR plates
were analyzed using an ABI Prism 7900 Sequence Detection
System (ABI) and Sequence Detection Software version 2.1
(ABI). Sample analyses were performed in duplicate.
2.5. Statistical Methods. Patient tumor characteristics and
SNP classiﬁcations were compared using Chi-squared and
Fisher’s exact tests as appropriate for categorical data and
t-tests and analysis of variance (ANOVA) for continuous
variables. Means ± standard deviations (SD) are reported
unless otherwise noted. A P-value of <0.05 was considered
statistically signiﬁcant. All analyses were performed using
SAS version 9.2.
3. Results
3.1. Characterization of Patient Tumors. Clinicopathologic
data included histologic subtype, primary site, age at diag-
nosis, gender, and race/ethnicity (Table 2). The majority of
patients were non-Hispanic Caucasians (74.4%), while 6.7%
ofpatientswereHispanic,and9.3%wereAfricanAmericans.
There were 45 male and 30 female pediatric RMS patients
ranging in age from 3 months to 18 years. There was no
diﬀerence in mean age by histologic subtype: age for ERMS
was 7.1 ± 5.1 years and for ARMS was 7.0 ± 5.1 years.
A large diversity of primary sites showed that the tumors
could arise almost anywherein the body. When the sites were
grouped, extremities represented the single most common
site (N = 19; 25.3%), followed by genitourinary (N = 18;
24.0%),headandneck(N = 11;14.7%),andabdomen(N =
9; 13.3%) (Table 2). Tumors occurring in extremities had
predominantlyARMShistology(15/19),whilegenitourinary
tumors had predominantly ERMS histology (15/18). Tumors
in trunk and visceral locations all had ARMS histology.
The age at diagnosis diﬀered signiﬁcantly with primary site
(P = 0.035). The youngest age at diagnosis was observed
for pelvic tumors (mean age ± standard deviation was 2.8 ±
1.0 years, resp.) and the oldest for genitourinary tumors
(10.2 ± 5.0 years). Patients with abdominal tumors were
signiﬁcantly younger at diagnosis (P = 0.05). We also ob-
served a signiﬁcant diﬀerence (P = 0.012) between tumor
primary sites by gender, with genitourinary and abdominal
tumors predominantly observed in males (15/18 and 8/10,
resp.) and head and neck tumors in females (9/11).
Seventy ﬁve RMS tumor samples were analyzed for TP53
mutations in exons 4–9 by direct sequencing. We identiﬁed
only a single TP53 mutation present in exon 7, c.775G/T
(p.D259Y). This missense mutation leads to loss of p53
function. The patient harboring this mutation was a one-
year-oldCaucasianboywithERMStumorontherightthigh,
tumor stage was not obtained. By analyzing sequencing data,
we have also observed a number of variants in the TP53
gene. In addition to SNP72, the most prevalent SNP was rs
no.1800372 (A/G at third base of codon 213, not changing
protein sequence), observed in 4 RMS tissues (5.3%). The
prevalence of G allele in our study was slightly higher than
the one reported in dbSNP for the US population (1%).
MDM2 ampliﬁcation frequency was analyzed in 22 RMS
tumor samples by diﬀerential PCR. No MDM2 ampliﬁcation
wasdetectedinDNAisolatedfromanyofthesesamples(data
not shown).
We have also analyzed the polymorphisms in MDM2
SNP309 and TP53 SNP72 in DNA isolated from frozen-
tumor samples (N = 40) (Table 3). For MDM2 SNP309 we
observed the following genotype frequencies: 40% for T/T,
40% for T/G, and 20% for G/G. These frequencies are
similar to those previously reported in healthy Caucasians
[11, 26, 27]. The mean age of diagnosis was 6.4 years for
T/T, 6.7 years for T/G, and 7.6 years for G/G MDM2 SNP4 Sarcoma
Table 2: Patient and tumor characteristics.
Characteristics
Histologic subtype
ARMS
(N = 37)
ERMS
(N = 38)
Sex
Male 18 27
Female 19 11
Mean age (STDEV), years
Boys 5.5 (4.6) 7.4 (5.0)
Girls 8.5 (5.3) 6.0 (5.1)
Race/ethnicity
Caucasian 26 30
African American 3 4
Hispanic 2 3
Other 6 1
Tumor site
Head and neck 7 4
Upper extremity 5 1
Lower extremity 10 3
Trunk 3 0
Abdomen 2 8
Visceral 4 0
Retroperitoneal 2 4
Pelvic 1 3
Genitourinary 3 15
alleles and are not statistically diﬀerent from each other
(P = 0.85). For the TP53 SNP72, the frequencies of C/C,
C/G, and G/G genotypes in rhabdomyosarcoma were 60%,
30%, and 10%, respectively, which were similar to those in
healthyCaucasians[28,29].Althoughthemeanageoftumor
onset in C/C genotype carriers was slightly lower compared
tothosewithC/GorG/Ggenotypes(6.3±5.2versus7.5±4.8,
and 7.0 ± 4.8, resp.), these diﬀerences were not signiﬁcant
(P = 0.78). We have also analyzed the eﬀect of either pol-
ymorphism (MDM2 SNP309 or TP53 SNP72) on the tumor
subtype and observed no association. Likewise, there was no
association between any SNP and tumor primary site.
Because MDM2 SNP309G and TP53 SNP72Arg have
been reported to act synergistically and were together asso-
ciated with the lowest age of cancer onset in carriers [10],
we examined whether these variants may act together in
sporadic RMS to confer increased risk of cancer onset at
ay o u n g e ra g e( T a b l e4). Only a single patient possessed
the protective genotype, reported to be associated with later
cancer onset in germline TP53 mutation carriers [10]( 0a t
risk loci shown in Table 4), and although patients with less
favorablegenotypesappearedtobeslightlyyoungeratcancer
diagnosis, these diﬀerences were not statistically signiﬁcant
(P = 0.78).
4. Discussion
A wide range of prevalences of TP53 mutations in RMS
were reported in the literature, with larger studies tending
to report lower mutation frequencies. To address these
inconsistencies, we have analyzed TP53 mutations in exons
4–9 in 75 pediatric RMS tumor samples, as the majority
of TP53 mutations occur in exons 5–8. We detected only a
single mutation in exon 7 (c.775G/T, p.D259Y), associated
with loss of p53 activity [30]. This occurred in a 1-year-old
patient with ERMS. ERMS are characterized by an earlier age
of onset compared to ARMS, with approximately half of all
cases diagnosed before the age of 5 years. Interestingly, the
tumor of this patient was located in the lower extremity, a
site that is more frequently associated with ARMS tumors.
All tumor samples in this study came from the CHTN,
which includes a central pathology review. However, the
majority of samples did not have accompanying data on
the percentage of tumor present in each sample or the
prevalence of necrosis. We therefore performed hematoxilin
staining of the available histopathology slides and reviewed
all histopathology slides to complete these data. This helped
us address the possibility that the observed low prevalence
of mutations in these tumors may be due to a large content
of normal tissue compared to tumor tissue in our samples,
which might undermine the detection of mutations that may
be present in tumor. However the pathology review deter-
mined that, except for two samples, that had approximately
60% of the sample composed of tumor tissue, at least 80% of
all other samples was tumor tissue. All reviewed samples had
over90%viablecellspresent.Therefore,itisunlikelythatthe
composition and integrity of our samples may have aﬀected
the observed low prevalence of TP53 mutations.
Diﬀerences in the methods used to identify mutations
in earlier compared to more recent studies may partially
accountfortheobserveddiﬀerencesinmutationfrequencies.
All earlier studies used single strand conformation polymor-
phism (SSCP), a method shown to more frequently detect
TP53 mutation detection, compared to sequencing, which is
current gold standard [31, 32].
Some clinicopathologic characteristics of our samples
wereinlinewithwell-establisheddiﬀerencesbetweenthetwo
major RMS subtypes, including diﬀerences in primary sites,
and equal male to female ratio among ARMS cases [2]. In
contrast, earlier age of onset of ERMS compared to ARMS
was not reﬂected in our samples (Table 2). Despite slightly
older age of ERMS cases than anticipated, the proportion of
very young children (up to 5 years of age) was substantial
(34/75), indicating that the age may not explain the observed
low mutation prevalence. Namely, among germline TP53
carriers, RMS occured very early in life and many developed
R M Sb e f o r et h ea g eo f5y e a r s[ 33]. By analogy, if sporadic
RMS tumors harboring TP53 mutations were more likely to
occur in younger children, a study not including this age
category would likely report lower prevalence of TP53 mu-
tations. There was a disproportionately higher number of
males than females with ERMS in our study compared to the
reported 1.3 male to female ratio. As we observed no gender
diﬀerences, gender distribution was unlikely to aﬀect our
results.
To explore whether increased levels of MDM2 may
provideanalternativemechanismtoTP53genemutation,we
have analyzed MDM2 gene ampliﬁcations. OverexpressionSarcoma 5
Table 3: Mean age of ﬁrst tumor onset according to MDM2 SNP309 or p53 codon 72 genotype.
Allele (frequency) Genotype Number of
patients (%) Mean age ± STDEV (years)
MDM2 SNP309
T (60%) T/T 16 (40) 6.4 ± 5.2
T/G 16 (40) 6.7 ± 5.4
G (40%) G/G 8 (20) 7.6 ± 3.7
T/G + G/G 24 (60) 7.0 ± 4.8
P53 codon 72 SNP
Arg (75%) Arg/Arg 24 (60) 6.3 ± 5.2
Arg/Pro 12 (30) 7.5 ± 4.8
Pro (25%) Pro/Pro 4 (10) 7.0 ± 4.8
Arg/Arg + Arg/Pro 36 (90) 6.7 ± 5.0
Table 4: Mean age of ﬁrst tumor onset according to the combined MDM2 SNP309 or p53 codon 72 genotype.
Number of at risk loci Corresponding genotypes Number of patients Mean age ± STDEV (years)
0 T/T + Pro/Pro 1 9.0 ± 0.0
1 ( T / Go rG / G+P r o / P r o )o r( T / T+A r g / A r go rA r g / P r o ) 1 8 6 . 2± 5.2
2 T/G or G/G + Arg/Arg or Arg/Pro 21 7.1 ± 4.8
or ampliﬁcation has been observed in a number of human
cancers [34, 35] suggesting that it may act as an alternative
mechanism to attenuate wild-type p53 function. Although
MDM2 ampliﬁcations were frequently observed in soft
tissue sarcoma [34, 35], the only study examining this in
pediatric RMS has shown very low prevalence of MDM2
ampliﬁcations (2 out of 20 samples) [22]. In addition, a
study that included both pediatric and adult RMS patients
showed a similar prevalence (3 out of 18 patients) [21].
Our study conﬁrms the ﬁnding that the prevalence of
MDM2 ampliﬁcations in pediatric RMS may be low, as we
detected no MDM2 ampliﬁcations in the 22 samples we
analyzed. In contrast to the previous suggestion that MDM2
ampliﬁcations may be more likely found in ARMS tumors
compared to ERMS [21, 36], we observed no ampliﬁcations
in either tumor subtype.
Among the variants that aﬀect p53 degradation, MDM2
SNP309 was associated with earlier age of cancer onset
among germline TP53 mutation carriers [10]. In addition,
this SNP was reported to be associated with younger age of
onset of sporadic soft tissue sarcoma [11], but this study
included insuﬃcient number of RMS samples to determine
whether this association would be also observed for RMS.
In contrast, our study included a much larger number of
pediatric RMS samples, and we found no association be-
tweenMDM2SNP309andyoungerageoftumoronset.Like-
wise, TP53 SNP72 was reported to be associated with age of
tumor onset in carriers, where it was also shown to interact
with MDM2 SNP 309 to further reduce the age of tumor
onset. Such interactions have also been described in sev-
eral sporadic human malignancies; therefore, we examined
whether TP53 SNP72 may act as a modiﬁer in RMS. We
found no eﬀect of TP53 SNP72 on the age of tumor
diagnosis, nor any evidence of interaction between TP53
SNP72 and MDM2 SNP309 on the age of tumor onset.
Although our study was relatively large, it was focused
on pediatric RMS. Therefore, the range of ages at tumor
onset was narrower compared to other studies that reported
modifying eﬀects of the variants aﬀecting p53 degradation
in either germline TP53 carriers or other types of sporadic
cancer. In addition, molecular characteristics of RMS tumors
that occur in children may diﬀer from those that occur in
adults. Therefore, it remains possible that any modifying
eﬀects of the variants analyzed here would have been ob-
served if adult cases had been included in our study. Further
studies involving both pediatric and adult RMS patients
would be needed to explore this.
In conclusion, we observed low prevalence of TP53
mutations and no MDM2 ampliﬁcations in pediatric RMS.
This is diﬀerent from what has been found before, and due
to the sample size, ours is likely a more accurate ﬁnding.
Variants TP53 SNP72 and MDM2 SNP309 did not accel-
erate tumor development. TP53 may therefore not play an
important role in pediatric RMS development. The possible
inactivation of p53 function by other mechanisms thus re-
mains to be elucidated.
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